Pharmacogenetics of Cannabinoid Response

This study attempts to examine genetic influences on the effects of tetrahydrocannabinol (Δ9-THC), the active ingredient of marijuana, cannabis, "ganja", or "pot".

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COMT Gene Polymorphism Mental Disorders Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

VA Connecticut Healthcare System

West Haven, Connecticut, 06516, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

18 and 55 years (extremes included) on the day of the first dosing.

Exclusion criteria

Cannabis naïve individuals.

Treatment and study plan

delta 9 tetrahydrocannabinol

Drug

0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes

Other names: Marijuana, cannabis

Primary outcomes

Behavioral Measures

Time frame: Baseline, +15, +25, +60, +300

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

National Institute on Drug Abuse (NIDA)

Registry information

Important dates

Study start: 2007
Primary completion: 2014
Study completion: 2014
First posted: May 15, 2008
Registry last updated: Mar 9, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed